Navigation Links
BGI and ACRG announce collaboration to accelerate cancer research in Asia
Date:2/17/2012

Shenzhen, China - BGI, the world's largest genomics organization and Asia Cancer Research Group (ACRG), a not-for-profit organization established to accelerate research and ultimately improve treatment for patients affected with the most commonly-diagnosed cancers in Asia, jointly announced a new collaboration on cancer genomics research as part of ACRG's mission to generate a unique and best-in-class data source on cancers prevalent in Asia, and to accelerate research and development of improved treatments for those cancers by freely sharing the resulting data with the scientific community.

The two parties will work together to conduct genomic research on lung cancer and liver cancer, two of the most common cancers in Asia. Lung cancer is one of the most common cancers for males and causes about 1.3 million deaths globally per year. The incidence of lung cancer has risen dramatically for both males and females in Asia in past decades. Liver cancer is the sixth most commonly diagnosed cancer and the third leading cause of cancer death. Hepatocellular carcinoma (HCC), the most common type of liver cancer, causes nearly 700,000 deaths worldwide annually, half of which occur in China.

BGI and ACRG will conduct the lung and liver cancer studies at the genomic level. ACRG will provide samples of lung and liver cancer tissues, and BGI will sequence these samples on its large-scale next-generation sequencing platforms, produce high-quality data output and provide bioinformatics analysis.

"The collaboration will accelerate the establishment of a pharmacogenomic database for Asian lung and liver cancers," said Dr. Mao Mao, President of ACRG. "Through this collaboration and the subsequent sharing of information with the broader scientific community, we are hoping to increase our knowledge of these two common cancers in Asia, and to accelerate the development of new diagnostic methods and therapies."

"We are very excited about this new partnership with ACRG. Given BGI's expertise in genomics research and ACRG's advances in cancer studies, I believe this partnership will accelerate cancer research, from understanding the basic mechanism to developing effective treatments for cancer," said Professor Huanming Yang, Chairman of BGI. "It's our first time applying comprehensive solutions to cancer research, and we believe the study will bring new perspectives for researchers that could facilitate biotechnology and pharmaceutical research in the future." he added.


'/>"/>
Contact: Jia Liu
liujia@genomics.cn
BGI Shenzhen
Source:Eurekalert

Related biology news :

1. A major prize in the chemical sciences announced by the Camille and Henry Dreyfus Foundation
2. 2008 SNM Wagner-Torizuka Fellowships announced
3. NIAID announces 25 new awards to develop radiation countermeasures
4. Aware Announces Q3 2008 Earnings Conference Call
5. Governor Doyle announces historic genomic research collaboration
6. BIO-key(R) Announces Additional $245,000 in Third Quarter Public Safety Orders
7. San Diego Supercomputer Center and UCSD announce Triton Resource
8. NARSAD announces 2008 Prizes for Outstanding Achievement in Research on Mental Health Disorders
9. GUMC and Oak Ridge National Labs announce unique research partnership
10. Parkinsons Disease Foundation announces award of $150,000
11. Jefferson Department of Surgery announces new pancreas tumor registry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)...  VoiceIt is excited to announce its new ... By working together, VoiceIt and VoicePass will offer ... take slightly different approaches to voice biometrics, collaboration ... usability. Both ... "This marketing and technology partnership allows ...
(Date:5/9/2016)... , UAE, May 9, 2016 ... when it comes to expanding freedom for high net ... Even in today,s globally connected world, there is ... conferencing system could ever duplicate sealing your deal with ... obtaining second passports by taking advantage of citizenship via ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... 23, 2016  The Biodesign Challenge (BDC), a university ... to harness living systems and biotechnology, announced its winning ... New York City . ... showcased projects at MoMA,s Celeste Bartos Theater during the ... MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory ... technical consulting, provides a free webinar on Performing Quality Investigations: Getting ... at 12pm CT at no charge. , Incomplete investigations are still a major ...
Breaking Biology Technology: